Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease
Authors
Keywords
-
Journal
Frontiers in Neurology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-03-26
DOI
10.3389/fneur.2021.645706
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Pharmacologic Treatment of Motor Symptoms Associated with Parkinson Disease
- (2020) Werner Poewe et al. NEUROLOGIC CLINICS
- EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease
- (2020) Caroline M. Tanner et al. Journal of Parkinsons Disease
- Non‐motor symptom burden is strongly correlated to motor complications in patients with Parkinson’s disease
- (2020) D. Santos‐García et al. EUROPEAN JOURNAL OF NEUROLOGY
- Should there be less emphasis on levodopa‐induced dyskinesia in Parkinson's disease?
- (2019) K. Ray Chaudhuri et al. MOVEMENT DISORDERS
- Dyskinesia matters
- (2019) M. Angela Cenci et al. MOVEMENT DISORDERS
- Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease
- (2018) Lawrence W. Elmer et al. CNS DRUGS
- Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials
- (2018) Rajesh Pahwa et al. PARKINSONISM & RELATED DISORDERS
- Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3)
- (2017) Wolfgang Oertel et al. MOVEMENT DISORDERS
- An updated meta-analysis of amantadine for treating dyskinesia in Parkinson’s disease
- (2017) Min Kong et al. Oncotarget
- ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study)
- (2017) Rajesh Pahwa et al. JAMA Neurology
- Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial
- (2016) Joaquim J Ferreira et al. LANCET NEUROLOGY
- Technology in Parkinson's disease: Challenges and opportunities
- (2016) Alberto J. Espay et al. MOVEMENT DISORDERS
- Quality of life in Parkinson's disease patients with motor fluctuations and dyskinesias in five European countries
- (2014) Marlene C. Hechtner et al. PARKINSONISM & RELATED DISORDERS
- Parkinsonian Patients and Poor Awareness of Dyskinesias
- (2014) Sara Pietracupa et al. Frontiers in Neurology
- Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial
- (2013) Robert A Hauser et al. LANCET NEUROLOGY
- Patient and caregiver perceptions of the social impact of advanced Parkinson’s disease and dyskinesias
- (2012) Alexander Khlebtovsky et al. JOURNAL OF NEURAL TRANSMISSION
- Quality of Life in Relation to Mood, Coping Strategies, and Dyskinesia in Parkinson's Disease
- (2009) Sébastien Montel et al. JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
- Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results
- (2008) Christopher G. Goetz et al. MOVEMENT DISORDERS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More